A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus
- PMID: 19762360
- DOI: 10.1136/ard.2009.115535
A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus
Abstract
Objective: To investigate whether the risk allele for systemic lupus erythematosus (SLE) in the signal transducer and activator of transcription factor 4 (STAT4) gene, defined by the single nucleotide polymorphism (SNP) rs10181656(G), is associated with vascular events and/or presence of prothrombotic anti-phospholipid antibodies (aPL) in patients with SLE.
Methods: Two independent groups of unrelated patients with SLE of Swedish ethnicity (n=424 and 154) were genotyped, and occurrence of previous manifestations of ischaemic heart disease (IHD), ischaemic cerebrovascular disease (ICVD) and venous thromboembolic events (VTE) was tabulated. aPL values were measured by ELISA. Matched controls (n=492 and 194) were genotyped.
Results: The STAT4 risk allele was more frequent in patients with SLE with previous arterial events (combined OR (OR(c))=1.5, 95% CI 1.1 to 2.0) compared to patients without such events. The association was mainly attributable to an accumulation of the risk allele among patients with ICVD (OR(c)=2.3, CI 1.6 to 3.3). There was no association with IHD or VTE. The presence of two or more aPLs was associated with the risk allele (OR(c)=1.6, 95% CI 1.2 to 2.0). In multivariable-adjusted logistic regression analyses treatment for hypertension, at least one STAT4 risk allele, older age, IgG anti-cardiolipin antibodies and longer SLE duration remained independently associated with previous ICVD (p<or=0.02 for all).
Conclusion: Patients with SLE with the STAT4 risk allele had a strikingly increased risk of ICVD, comparable in magnitude to that of hypertension. The results imply that a genetic predisposition is an important and previously unrecognised risk factor for ICVD in SLE, and that aPLs may be one underlying mechanism.
Similar articles
-
HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus.Ann Rheum Dis. 2013 Jun;72(6):1018-25. doi: 10.1136/annrheumdis-2012-201760. Epub 2012 Aug 14. Ann Rheum Dis. 2013. PMID: 22893315
-
Cigarette smoking, STAT4 and TNFRSF1B polymorphisms, and systemic lupus erythematosus in a Japanese population.J Rheumatol. 2009 Oct;36(10):2195-203. doi: 10.3899/jrheum.090181. Epub 2009 Aug 14. J Rheumatol. 2009. PMID: 19684152
-
Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population.Arthritis Rheum. 2008 Jul;58(7):1940-6. doi: 10.1002/art.23494. Arthritis Rheum. 2008. PMID: 18576330
-
Polymorphisms in STK17A gene are associated with systemic lupus erythematosus and its clinical manifestations.Gene. 2013 Sep 25;527(2):435-9. doi: 10.1016/j.gene.2013.06.074. Epub 2013 Jul 13. Gene. 2013. PMID: 23860322 Review.
-
What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE.Lupus. 2010 Oct;19(12):1452-9. doi: 10.1177/0961203310370350. Lupus. 2010. PMID: 20947557 Review.
Cited by
-
Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.Clin Immunol. 2012 Jun;143(3):210-21. doi: 10.1016/j.clim.2012.03.005. Epub 2012 Apr 6. Clin Immunol. 2012. PMID: 22525889 Free PMC article. Review.
-
Genetic polymorphisms in genes involved in the type I interferon system (STAT4 and IRF5): association with Asian SLE patients.Clin Rheumatol. 2024 Aug;43(8):2403-2416. doi: 10.1007/s10067-024-07046-8. Epub 2024 Jul 4. Clin Rheumatol. 2024. PMID: 38963465 Review.
-
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.Lupus Sci Med. 2020 Oct;7(1):e000424. doi: 10.1136/lupus-2020-000424. Lupus Sci Med. 2020. PMID: 33037080 Free PMC article. Clinical Trial.
-
Neutrophils-Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome.Front Immunol. 2019 Nov 22;10:2734. doi: 10.3389/fimmu.2019.02734. eCollection 2019. Front Immunol. 2019. PMID: 31824510 Free PMC article. Review.
-
Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers.Fukushima J Med Sci. 2020 Apr 22;66(1):1-9. doi: 10.5387/fms.2020-02. Epub 2020 Mar 13. Fukushima J Med Sci. 2020. PMID: 32173681 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous